Singapore markets closed

IOVA Jun 2024 12.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.60000.0000 (0.00%)
At close: 12:44PM EDT
Full screen
Previous close0.6000
Open0.6000
Bid0.0000
Ask0.1000
Strike12.50
Expiry date2024-06-14
Day's range0.6000 - 0.6000
Contract rangeN/A
Volume5
Open interest60
  • Simply Wall St.

    Exploring Three US Growth Companies With Substantial Insider Ownership

    Amidst a backdrop of fluctuating markets and evolving economic indicators, the U.S. stock market has shown resilience in various sectors despite recent downturns in tech giants. As investors navigate through these uncertain times, understanding the role of insider ownership in growth companies becomes increasingly relevant. In this environment, companies with substantial insider ownership can be appealing as they often indicate a leadership team deeply invested in the company's long-term...

  • GlobeNewswire

    Iovance Biotherapeutics to Present at Upcoming Conferences and Events

    SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences and events: TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHAFireside Chat: May 28, 2024 at 3:00 p.m. ETVirtual Iovance ASCO Invest

  • Zacks

    Iovance (IOVA) Up 5% on Updated Data From Melanoma Study

    Iovance (IOVA) shares updated data from a mid-stage study, which showed that treatment with its combination therapy achieved an objective response rate of 65% in frontline advanced melanoma.